Charles River LaboratoriesCRL
CRL
$233.47
5.26%
Market Cap: 12B
0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 12 analysts
0
News positive %
of 8 articles
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
88% more funds holding in top 10
Funds holding in top 10: 8 [Q4 2023] → 15 (+7) [Q1 2024]
68% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 53
14% more capital invested
Capital invested by funds: $12.3B [Q4 2023] → $14B (+$1.75B) [Q1 2024]
11% more repeat investments, than reductions
Existing positions increased: 248 | Existing positions reduced: 223
6% more funds holding
Funds holding: 619 [Q4 2023] → 655 (+36) [Q1 2024]
0.23% less ownership
Funds ownership: 109.99% [Q4 2023] → 109.77% (-0.23%) [Q1 2024]
47% less call options, than puts
Call options by funds: $52M | Put options by funds: $98.3M
Research analyst outlook
12 Wall Street Analysts provided 1 year price forecasts over the past 6 months
Low target
$228
2%
downside
Avg. target
$261
12%
upside
High target
$290
24%
upside
12 analyst ratings
8 positive
67%
4 neutral
33%
0 negative
0%
Baird Eric Coldwell | 2%upside $239 | Outperform Maintained | 10 Jul 2024 |
Barclays Luke Sergott | 1%downside $230 | Equal-Weight Initiated | 28 Jun 2024 |
Mizuho Ann Hynes | 1%upside $235 | Neutral Initiated | 7 Jun 2024 |
Goldman Sachs Matthew Sykes | 24%upside $290 | Buy Initiated | 6 Jun 2024 |
TD Cowen Charles Rhyee | 2%downside $228 | Hold Maintained | 13 May 2024 |
Financial journalist opinion
Based on 8 articles about CRL published over the past 30 days